Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTIS2023-507991-32-00
CTIS2023-507991-32-00Active, not recruitingPhase 1

LACOS-06-23

Sun Pharmaceutical Industries Limited0 sites32 target enrollmentStarted: October 26, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
32
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 64 (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Similar Trials

Active, not recruiting
Phase 1
Clinical trial to compare availability in the body of the active substance nicotine as well as patch adhesion of the newly developed patch LTS Nicotine TTS (18.6 cm2) vs. Nicotinell® (21 mg/24 h) in healthy smokers after single patch applicatiobioequivalence and patch adhesion trialtherapeutical indication not studiedMedDRA version: 20.0Level: PTClassification code: 10057852Term: Nicotine dependence Class: 100000004873MedDRA version: 20.0Level: PTClassification code: 10053325Term: Smoking cessation therapy Class: 100000004865MedDRA version: 20.0Level: LLTClassification code: 10008374Term: Cessation of smoking Class: 10041244
CTIS2023-503548-14-00TS LOHMANN Therapie-Systeme AG72
Active, not recruiting
Phase 1
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors
CTIS2023-509867-26-00Eli Lilly & Co.112
Active, not recruiting
Phase 1
RANDOMISED, CROSSOVER, SIMPLE-BLINDED, BIOEQUIVALENCE CLINICAL TRIAL OF ALMOTRIPTAN 12.5 MG ORODISPERSIBLE TABLETS VERSUS ALMOTRIPTAN 12.5 MG FILM-COATED TABLETS, AFTER A SINGLE ORAL DOSE ADMINISTRATION TO HEALTHY VOLUNTEERS UNDER FASTING
CTIS2023-508747-49-00Qualix Pharma S.L.28
Recruiting
Phase 1
A Phase 1, open label, randomized, 2-sequence, 2-period, crossover, single center study to evaluate the pharmacokinetics of follitropin alfa from 2 manufacturing processes, administered as a single subcutaneous 450 IU dose to pituitary-suppressed healthy premenopausal female participants.Infertility
CTIS2023-507066-91-00Merck Healthcare KGaA14
Active, not recruiting
Phase 1
APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer)
CTIS2023-506975-83-00Aprogen Inc.720
An open label, balanced, randomized,... | Clinical Trial